MCL1 and breast cancer: Overall, these studies demonstrate ERα+ breast cancers treated with standard of care endocrine inhibitors may induce Mcl-1 expression and/or activity, which could represent a potential dynamic biomarker of sensitivity to Mcl-1 inhibition.